SamaCare provides a cloud-based workflow automation platform that helps medical practices streamline specialty drug prior authorization, patient enrollment, and benefit verification. It also delivers premium services and data analytics to pharmaceutical brands to improve access to therapy. The company works with pharmaceutical manufacturers, providers, payors, and other stakeholders. SamaCare serves retina, oncology, neurology, and rheumatology practices that together account for over $20 billion in annual specialty drug spend. Led by CEO and founder Syam Palakurthy, the company says it continues to grow quickly. The company intends to use new funding to accelerate product development of its one-stop patient access platform. SamaCare offers a portal that lets medical practices submit, track, and manage prior authorizations for specialty and physician-administered medications across payers and drugs. The platform replaces disconnected spreadsheets, unstructured EMR notes, and insurer-specific portals, automating status tracking so staff do not need to manually check approvals. It is free for medical practices and monetizes via premium features sold to pharmaceutical manufacturers, including region-specific data and patient-enrollment tools such as nurse support, adherence programs, and financial assistance. Operational metrics cited include over 2,300 prescribers on the platform, a 43% reduction in time spent on prior authorization, a 22% increase in administrative denials, a 70% reduction in time-to-treatment for pharmaceutical customers, and a 20% increase in first-time approval rates for drugs. The company says it will use the funding to expand practice penetration across existing and new specialties, ramp up customer acquisition and pharmaceutical support, and hire executives to lead provider growth, customer success, operations, product, and engineering. SamaCare’s stated mission is to remove avoidable administrative obstacles so patients receive therapy based on clinical need rather than administrative or financial burdens.

Total raised

$29M

Funding rounds

2

Latest round

Series B

Latest activity

May 2024